CNS Pharmaceuticals, Inc. (CNSP)
- Previous Close
1.2600 - Open
1.1700 - Bid --
- Ask 1.6000 x 100
- Day's Range
1.1700 - 1.2600 - 52 Week Range
0.7720 - 800.0000 - Volume
161,667 - Avg. Volume
1,830,845 - Market Cap (intraday)
3.71M - Beta (5Y Monthly) 0.77
- PE Ratio (TTM)
-- - EPS (TTM)
-1,943.5000 - Earnings Date Aug 12, 2025 - Aug 18, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
200.00
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate TPI 287 and Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma and other CNS malignancies. CNS Pharmaceuticals, Inc. has license agreements with Houston Pharmaceuticals, Inc., Cortice Biosciences, Inc., and The University of Texas M.D. Anderson Cancer Center, as well as a collaboration and asset purchase agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
www.cnspharma.comRecent News: CNSP
View More
Performance Overview: CNSP
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CNSP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CNSP
View MoreValuation Measures
Market Cap
3.71M
Enterprise Value
-2.43M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.60
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-179.08%
Return on Equity (ttm)
-1,703.39%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-14.86M
Diluted EPS (ttm)
-1,943.5000
Balance Sheet and Cash Flow
Total Cash (mrq)
6.46M
Total Debt/Equity (mrq)
5.28%
Levered Free Cash Flow (ttm)
-13.27M